TETRA BIO-PHARMA INC Stock News

Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1) announced that it has executed a non-binding term sheet with Avicanna Inc. (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) to assess entering into a strate

Tetra Bio-Pharma Inc. (TSX: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development announced on Monday that it produced positive initial clinical data from its ongoing P

Tetra Bio-Pharma Inc shared a progress report on its development of its lead investigational drug QIXLEEF, a THC and CBD inhaled product for treatment of breakthrough pain. The pharmaceutical firm sai

OTTAWA, ON, Oct. 14, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today

Tetra Bio-Pharma Inc. said the company had achieved a “major milestone” through its first cannabinoid-derived medicine REDUVO as it announced that numerous pre-launch activities have been initiate

Tetra Bio-Pharma Inc, a cannabinoid-derived drug discovery and development company, revealed that it received positive feedback from a Scientific Advice Assessment (SAA) report from the Malta Medicine

Tetra Bio-Pharma Inc, a cannabinoid-derived drug discovery and development company, revealed that it received positive feedback from a Scientific Advice Assessment (SAA) report from the Malta Medicine

SAA Report endorsed Tetra Bio-Pharma's proposed nonclinical development and quality programs for QIXLEEF™. SAA Report provides clarity on clinical requirements for registration in Europe.

Tetra Bio-Pharma Inc. said it has filed a PCT patent application for 'Cannabis Plant Residue and Use Thereof', under PCT Patent Application No.

OTTAWA, ON, July 29, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc ("Tetra" or the Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announ

Tetra Bio-Pharma Inc said it has engaged Christine Caron as a patient partner to actively collaborate in research, knowledge translation, and patient engagement within the pain and sepsis communiti

Important step for Tetra to ensure meaningful collaboration and patient engagement in research. OTTAWA, ON, July 22, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) said it is accelerating its REBORN1 trial of its proprietary cannabinoid-based drug candidate QIXLEEF after receiving approval allowing the stud

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) said it is accelerating its REBORN1 trial of its proprietary cannabinoid-based drug candidate QIXLEEF after receiving approval allowing the stud

Ethics Committee approves REBORN1© protocol amendment allowing for the addition of two immediate release oral opioids to be compared against QIXLEEF™. REBORN1© is the first of its kind proof-of-co